

PRESS RELEASE



Patent protection for *DermaPro*® expanded: CytoTools AG consolidates its position in licensing negotiations

- Issue of additional patents in the US plus further progress in Europe creates potential for target global marketing of *DermaPro*®
- High level of interest in *DermaPro*® amongst trade professionals
- Preparations for market launch in India on track

Darmstadt, 21 December 2012 – CytoTools AG, a technology holding with interests in the pharma and medical product sector has announced further successes in the expansion of its patent portfolio. In October this year, the American Patent Office issued an additional patent for tissue repair to its core product *DermaPro*®, which subsidiary DermaTools Biotech GmbH is continuing to develop in various trials. There is further good news about a procedure pending at the European Patent Office: the processing of an application has now reached the point where we can also expect to see another patent issued in the near future.

"These decisions will help strengthen industrial property rights for *DermaPro*® and consolidate our position in future licensing negotiations with the goal of global use of marketing rights in key markets," explained Dr. Dirk Kaiser, Managing Director of DermaTools Biotech GmbH with reference to the recent patent success stories.

The high level of scientific interest, especially on the Indian market, is further testament to the huge potential of *DermaPro*®. In a joint presentation by CytoTools and the Indian licensee Centaur Pharmaceuticals at this year's autumn conference of the Indian diabetic foot ulcer society, the medical product was presented to the general public. "*DermaPro*®'s amazing effectiveness and the enormous demand for our innovative product was again confirmed by various medical specialists, validating our trial results to date," said Kaiser.

Discussions are ongoing between the Board of CytoTools AG and the management of Centaur Pharmaceuticals concerning the organisation of further scientific events in India and the coordination of the market launch planned for next year. A decision will also be made on a production start date for the first batches of *DermaPro*® destined for the Indian market.

This release contains specific future-oriented statements. These reflect the opinion of CytoTools on the date of this release. The actual results achieved by CytoTools could substantially deviate from the future-oriented statements made. CytoTools is not obligated to update these future-oriented statements.

PRESS RELEASE



CytoTools

CytoTools AG, previously CytoTools GmbH, is a technology and holding company which holds the following shares in its subsidiaries which carry out product development in the pharmaceutical and medical products field: approx. 60% in DermaTools Biotech GmbH (therapy field dermatology, urology) and 46% in CytoPharma GmbH (therapy field cardiovascular disease, cancer). The complete know-how is protected by corresponding basic patents which are maintained worldwide by CytoTools AG and transferred to the subsidiary companies in the form of exclusive licenses.

Contact:

CytoTools AG
Dr. Mark Andre Freyberg
Klappacher Str. 126
64285 Darmstadt, Germany
Tel.: +49-6151-95158-12
Fax: +49-6151-95158-13
E-Mail: freyberg@cytotools.de

Press contact:

cometis AG
Ulrich Wiehle
Unter den Eichen 7
65195 Wiesbaden, Germany
Tel.: +49-611-205855-11
Fax: +49-611-205855-66
E-Mail: wiehle@cometis.de